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IL-1β, stimulated with IL-1β and Tendoactive® or pre-stimulated
with Tendoactive® followed by co-treatment with Tendoactive®
and IL-1β. Cell viability, adhesion, proliferation and the produc-
tion of ECM were analysed with light microscopy and transmis-
sion electron microscopy (TEM). Immunoﬂuorescence was used
to evaluate production of type I collagen, the main extracellu-
lar matrix protein produced by tenocytes. We also studied the
expression of the signal transduction and adhesion molecule β1-
integrin.Western Blotting (WB) was performed to evaluate the ex-
pression of apoptotic and inﬂammatory markers (metalloprotease-
1 (MMP-1), cyclooxygenase-2 (Cox-2) and caspase-3).
Results: Tendoactive® had a potent stimulatory effect on human
tenocyte proliferation and ECM production and was also able
to suppress the catabolic, apoptotic and inﬂammatory effects
induced by IL-1β in human tenocytes. This was demonstrated by
the suppression of IL-1β-induced expression of MMP-1, Cox-2 and
caspase-3 and up-regulation of type I collagen and β1-integrin.
Conclusions: The results presented suggest that this formulation
inhibits catabolic and inﬂammatory processes in an in vitro model
of tendonitis.Tendoactive® may therefore be used on prophylaxis
and treatment of tendinopathies to stimulate tendon healing, re-
generation and repair.
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Purpose: To evaluate the effectiveness of Tendoactive™ adminis-
tration in the treatment of 3 different tendinopathies, such as epi-
condylitis, supraspinous tendinopathy, achilles tendinopathy and
plantar fasciitis.
Methods: Twenty patients with each clinical condition, clinically
and ecographically veriﬁed, were enrolled between October 2007
and March 2008 resulting in a total of eighty participants. Patients
were randomly assigned to either a study group (n = 10) or a
control group (n = 10). During 3 months all the patients received
between 20 and 30 rehabilitation sessions. In addition the study
group consumed 2.16g/d of Tendoactive™, a food supplement
containing collagen, mucopolysaccharides and vitamin C. Pain,
SF36 quality of life survey, as well as standardized functional
assessment were evaluated before and 1, 2 and 3 months after
treatment.
Results: The study group displayed a signiﬁcant pain reduction
(P<0.05) in all the subgroups except for the epicondylitis group.
Pain reduction was associated with an improvement of at least
one SF36 subscale in each subgroup (P<0.05). At the end of the
treatment a signiﬁcant improvement in the functional assessment
of the physiotherapist was reported for all the tendinopathies
(P<0.05).
Conclusions: Our results suggest that the use of Tendoactive™
for the management of tendinopathies and plantar fasciitis is safe
and effective, leading to a signiﬁcant reduction in pain and im-
proving the biomechamical properties of the joint, without adverse
effects.
Pain: Clinical and Pathophysiology
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Purpose: A ﬁxed daily dose of ﬁve grams of a standardized
powder, made from hips of a Rose subspecies (Rosa canina),
produced using a standardized methodology by Hyben Vital, Den-
mark, has signiﬁcantly lowered symptom scores in patients with
osteoarthritis and shown anti-inﬂammatory properties. The aim of
the present study was to test whether there was any indication of
a dose dependent impact on the WOMAC pain score, from the
present rose hip powder, when evaluating a group of patients all
suffering from osteoarthritis of the hip and/or knee according to the
American College of Rheumatology criteria for the classiﬁcation of
osteoarthritis.
Methods: 52 patients, mean weight 78.3 kg (range 50 -122 kg),
were randomly allocated to either 3 month treatment with ﬁve
grams daily of encapsulated standardised rose hip powder, or ﬁve
grams of placebo. There were no signiﬁcant difference regarding
weight, sex, duration of the disease, educational background or
consumption of additional pain killers, when comparing the two
groups. WOMAC questionnaires were used throughout the study
and each patients noted his/hers daily consumption of rescue
medication in a diary. Data evaluation was based on intention
to treat (ITT). To search for a possible dose-dependency of the
present treatment, a non-parametric Spearman correlation test
was applied on the active treated group as well as the placebo
group.
Results: An overall reduction in WOMAC pain, WOMAC stiffness
and ADL function was observed as a result of active treatment
when compared to placebo (p<0.05). Moreover active treatment
resulted in a reduction in the consumption of rescue medica-
tion, as compared to the consumption observed during placebo
(p<0.05). There was a signiﬁcant negative correlation between
weight and reduction in pain score in the group treated with rose
hip (correlation coefﬁcient = - 0.39, p value = 0.019) after three
weeks treatment and (correlation coefﬁcient = - 0.41, p value =
0.014) after three months treatment. No negative correlation was
observed when a similar analysis was applied on placebo treated
patients. No signiﬁcant correlation to weight was observed when
evaluating changes in WOMAC stiffness or ADL function in any of
the two groups.
Conclusions: It is suggested that the present rose hip powder
reduces WOMAC scores and the consumption of rescue medica-
tion in patients suffering from osteoarthritis of the hip and/or knee.
Further more the present powder may act dose-dependently on
pain.
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Purpose: Avascular necrosis of the femoral head (AVN) is a
